Navigation Links
JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
Date:8/5/2010

CLEVELAND, Aug. 5 /PRNewswire/ -- JumpStart Ventures, which invests in and partners with innovative, early-stage companies in Northeast Ohio, announced an investment commitment of $250,000 in drug development company ChanRx. The two-year-old company is developing a pharmaceutical compound to treat atrial fibrillation, a heart condition that affects two million Americans, with 200,000 new cases being diagnosed each year.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20060209/CLJUMPSTARTLOGO )

(Logo:  http://photos.prnewswire.com/prnh/20060209/CLJUMPSTARTLOGO )

Atrial fibrillation is characterized by an irregular beating of the heart caused by misfiring of electrical impulses. The abnormal contracting causes decreased cardiac function, raising the risk of stroke and heart failure. An oral form of ChanRx's anti-arrhythmia drug, called Vanoxerine, has already demonstrated its ability to restore normal heart rhythm in a human clinical study. The study also showed an improved safety profile, as compared to other drugs in the market or currently in development. 

ChanRx, which is a spin-out from parent company ChanTest, will use a majority of the funding and the entrepreneurial development assistance provided by JumpStart Venture Partner, Kevin Mendelsohn, to complete development of an intravenous formulation of Vanoxerine. The intravenous formulation will enable quicker absorption and increased speed to efficacy when compared to other deliveries of the drug.  

"Drug therapy is the mainstay of treatment for this condition; unfortunately, the drugs used today have delivered unsatisfactory efficacy and undesirable safety profiles, including links to potentially lethal arrhythmias," said Arthur "Buzz" Brown, Founder of ChanRx. "ChanRx's pharmaceutical compound has demonstrated a superior safety profile in six previously conducted Phase I human clinical trials. We also showed in a Phase IIa trial that oral Vanoxerine is effective in restoration of normal cardiac rhythm. Taking the drug from an oral to an IV formulation will improve its effectiveness and this investment from JumpStart Ventures provides us with the resources and assistance we need to accelerate that process."

This investment represents JumpStart Ventures' 66th investment in its 49th company.

About ChanRx

ChanRx is a Cleveland-based drug development company focused on the commercialization of repurposed drug candidates. The company is a spin-out of ChanTest (www.chantest.com), a leading pharmaceutical testing service company which has developed the world's most complete library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. ChanRx is developing an intravenous (IV) formulation of a drug to treat atrial fibrillation.

About JumpStart Ventures

JumpStart Ventures (www.jumpstartinc.org/ventures) invests in and forges partnerships with innovative, early-stage Northeast Ohio companies that have the potential to generate $30 to $50 million in revenues in five to seven years. It helps companies accelerate their time to venture-readiness by bundling guidance from experienced Venture Partners with seed investment capital. JumpStart Ventures is the investment arm of JumpStart Inc., a nationally recognized non-profit organization creating economic transformation by providing resources to entrepreneurs leading high potential early-stage companies.


'/>"/>
SOURCE JumpStart Ventures
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. JumpStart Invests in Checkpoint Surgical
2. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
3. Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures
4. BIO Ventures for Global Health Opens San Francisco Office; Hires New Senior Staff
5. iPierian Closes $22 Million Series B Financing Led By Google Ventures
6. Phreesia to Accelerate Growth with $16 Million Investment Led by Ascension Health Ventures
7. Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC
8. ThermalTherapeutic Systems Completes $2.75 Million Series A Financing With Originate Ventures
9. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
10. 7 Health Ventures Invests in Tulip Medical
11. University of Michigan Wolverine Venture Fund Invests in Delphinus Medical Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... 21, 2017 Halo Labs announces the launch ... analysis system called the Horizon at PEGS 2017 in ... new system analyzes sub visible particulate matter in biopharmaceutical ... screening as early as candidate selection and pre-formulation. ... contract research organization Elion Labs for system ...
(Date:4/20/2017)... 20, 2017  Vivify Health, the pioneer and market ... awarded a very significant patent for the advancement of ... care via digital health.  This landmark patent provides the ... further secures Vivify,s position as the leader in remote ... the first company to apply consumer mobile devices, wireless ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Miami native and local periodontist ... “I could have never imagined back in 1991 that this journey would have taken ... Over the last 25 years, Dr. Gallardo has pioneered implant dentistry innovation, evolving into ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... proud to announce that it has received 510(k) clearance from the U.S. Food ... and the MyoCycle Pro. , Both devices are stationary cycling systems that use ...
(Date:4/25/2017)... NY (PRWEB) , ... April 25, 2017 , ... A ... stress at work can also decrease overall productivity and performance in the workplace. The ... employees. , During the last few weeks of April, Clearview Resolution Services will be ...
(Date:4/25/2017)... NV (PRWEB) , ... April 25, 2017 , ... ... now choose a modern procedure that achieves results in a fraction of the ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary treatment ...
(Date:4/25/2017)... ... ... B. Chaudhary, MD is committed to providing the highest quality of spine care to all ... care with all my patients to alleviate possible future issues. I am pleased to have ... office and my trained staff will assist you in any way possible.” , Dr. Saad ...
Breaking Medicine News(10 mins):